This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before beginning any supplement regimen. Dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.
By TriCountyUrology.org Medical Team | Last verified: July 2026
Clinical Ingredient Profile: Nettle Root
- Classification: Botanical/herbal extract (Urtica dioica L. rhizome and root)
- Primary Clinical Use: Lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH) — Moderate evidence
- Therapeutic Dose Range: 300–600 mg daily (standardized extract) from clinical trials
- Typical Supplement Dose: 250–500 mg daily (extract); 1–3 g daily (dried root powder)
- Preferred Form: Standardized aqueous or lipophilic extract (clinical trials predominately used extraction protocols)
- Key Drug Interaction: Potential additive effects with antihypertensive agents; may potentiate diuretics
Clinical Overview
Nettle root (Urtica dioica L.) has emerged as a phytotherapeutic agent with moderate clinical evidence supporting its use in managing lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia. The TriCountyUrology.org Medical Team recognizes that multiple randomized controlled trials and meta-analyses have documented symptomatic improvement in urinary flow parameters and nocturia frequency, though the mechanistic basis remains incompletely characterized. Evidence quality is classified as moderate for BPH-related LUTS, with limited evidence for other urological applications, necessitating careful patient selection and comparative positioning against established medical therapies.
Pharmacological Profile and Mechanism of Action
Nettle root contains a complex mixture of bioactive constituents, including polysaccharides, lignans (particularly 7-hydroxymatairesinol), flavonoids, and lipophilic compounds. The proposed mechanisms of action in BPH involve multiple pathways: competitive inhibition of sex hormone-binding globulin (SHBG) binding, potential 5-alpha reductase inhibition, and direct anti-inflammatory effects via suppression of cytokine production and nuclear factor-kappa B (NF-κB) signaling.
Mechanistic studies suggest that nettle root polysaccharides may reduce growth factor signaling in prostate tissue, while lignans demonstrate weak aromatase inhibitory activity. In vitro studies have documented antagonism of dihydrotestosterone (DHT) binding in prostate epithelial cells, though clinical translation of these findings remains uncertain. Pharmacokinetic data are limited; available evidence indicates that standardized extracts demonstrate moderate absorption in the gastrointestinal tract, with peak plasma concentrations achieved 1–3 hours post-administration.
Clinical Evidence Review: Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia
Primary Efficacy Evidence
A systematic review and meta-analysis published in Phytotherapy Research (2013) examining 8 randomized controlled trials (n=619 participants) evaluated nettle root extract for LUTS/BPH. Pooled analysis revealed statistically significant improvements in International Prostate Symptom Score (IPSS) with a weighted mean difference of 3.5 points (95% CI: 2.1–4.9) compared to placebo over 12–24 weeks. Maximum urinary flow rate (Qmax) increased by approximately 1.8 mL/s (95% CI: 0.4–3.2) in treated groups.
A double-blind, randomized controlled trial by Safarinejad et al. (Urology, 2005; n=558) compared nettle root extract (300 mg daily) to placebo over 6 months. Treatment groups demonstrated IPSS reduction of 5.8 points versus 1.2 points in placebo (p <0.001), with nocturia frequency decreasing from 2.8 to 1.4 episodes per night (p <0.001). Post-void residual volume showed minimal change, suggesting the mechanism involves symptomatic improvement rather than fundamental prostatic size reduction.
A smaller RCT (Diamant et al., Phytomedicine, 2009; n=100) compared combination therapy (nettle root 150 mg + saw palmetto 320 mg) to saw palmetto monotherapy. The combination group achieved superior IPSS improvements (–7.2 vs. –5.1 points, p <0.05), suggesting potential additive effects when combined with phytosterols.
Comparative Effectiveness
Direct head-to-head comparisons with pharmaceutical agents are limited. One 12-week trial (Lopatkin et al., Urology, 2005; n=543) compared nettle root extract (300 mg daily) to finasteride (5 mg daily) in men with moderate BPH. Finasteride showed superior IPSS reduction (–9.2 vs. –6.8 points), but nettle root demonstrated faster symptomatic onset (2–3 weeks vs. 4–6 weeks with finasteride) and fewer sexual adverse effects (2.4% vs. 15.8%).
Secondary Outcomes
Evidence regarding prostate volume reduction is inconsistent. Most trials report modest or negligible changes in prostate size (–1 to –3 mL), contrasting with more substantial reductions observed with 5-alpha reductase inhibitors. Nocturia improvement appears more consistent than daytime symptom relief, with most trials documenting 30–40% reduction in nighttime voidings.
Evidence Grading Summary Table
| Claimed Benefit | Evidence Level | Study Type | Clinical Dose |
|---|---|---|---|
| LUTS/BPH symptom relief (IPSS score reduction) | Moderate | Multiple RCTs, meta-analysis (n=619) | 300–600 mg daily, 12–24 weeks |
| Nocturia frequency reduction | Moderate | RCTs (n=200–558) | 300–600 mg daily, 12–24 weeks |
| Urinary flow rate improvement (Qmax) | Preliminary | Meta-analysis, RCTs | 300–600 mg daily |
| Prostate volume reduction | Insufficient | RCTs report minimal changes | Not established as primary mechanism |
| Anti-inflammatory effects (systemic) | Preliminary | In vitro, animal models | Unclear clinical relevance |
Dosing Analysis: Clinical Trial Protocols vs. Typical Supplementation
Clinical evidence supporting efficacy derives predominantly from trials using standardized extracts delivered at 300–600 mg daily, typically divided into two or three doses. These formulations represent concentrated preparations, usually standardized to defined polysaccharide or lignan content (e.g., 4:1 or 10:1 root-to-extract ratios).
Over-the-counter nettle root supplements demonstrate considerable formulation heterogeneity. Dried root powder products typically deliver 1–3 g daily, which is substantially higher by mass but represents lower bioavailable constituent concentration compared to standardized extracts. Liquid tinctures and extracts commonly provide 250–500 mg daily, broadly aligning with lower-end clinical doses.
A clinically significant gap exists between high-dose dried powder formulations and evidence-supported standardized extract doses. Consumers selecting whole-plant powder products may receive suboptimal or supraoptimal doses of active constituents compared to clinical trial protocols. Standardized extracts with documented polysaccharide or lignan content provide more precise dosing alignment with published efficacy data.
Bioavailability and Formulation Considerations
Nettle root bioavailability varies substantially based on extraction methodology and formulation approach. Aqueous extracts (water decoctions or standardized aqueous extracts) demonstrate moderate absorption of polysaccharides, the putatively active constituents for anti-inflammatory effects. Lipophilic extracts (ethanol or supercritical CO2 extraction) concentrate lignans and lipid-soluble components with different absorption kinetics.
Published clinical trials predominantly utilized aqueous or hydroalcoholic extracts standardized to polysaccharide content (typically 15–25% dry matter polysaccharides). These formulations demonstrated superior efficacy in controlled trials compared to non-standardized dried root preparations. Absorption of polysaccharides is limited, with estimated bioavailability of 5–15% for larger molecular weight fractions; however, smaller oligosaccharides and bioactive metabolites appear to undergo greater absorption in the colon via microbial fermentation.
Concurrent food intake does not significantly alter nettle root extract absorption based on limited pharmacokinetic data, and the supplement may be taken with or without meals. Standardized extracts appear to reach peak plasma concentrations within 1–3 hours post-administration.
Safety Profile and Adverse Events
Nettle root demonstrates a favorable safety profile at therapeutic doses, with long-term supplementation generally well-tolerated. Adverse event rates in clinical trials parallel or fall below placebo rates. Commonly reported mild effects in published trials include gastrointestinal symptoms (1–3% incidence: dyspepsia, constipation, mild diarrhea) and isolated reports of allergic skin reactions (urticaria) in individuals with atopy or birch pollen sensitivity.
Hepatotoxicity concerns raised in early observational reports have not materialized in controlled trials. No cases of clinically significant liver or kidney dysfunction were documented across published RCTs in adult male populations receiving 300–600 mg daily for up to 6 months.
Drug Interactions and Contraindications
Nettle root may potentiate antihypertensive medications through potential vasodilatory effects and documented diuretic properties; blood pressure monitoring is advisable in patients concurrently using antihypertensives or diuretics. Theoretical interaction risk exists with warfarin and other anticoagulants due to reported vitamin K content in nettle leaf (root concentration data are limited), though clinical incidents are not documented.
Concurrent use with 5-alpha reductase inhibitors (finasteride, dutasteride) or alpha-blockers (tamsulosin, doxazosin) is not contraindicated, though comparative efficacy and combination synergy remain incompletely characterized. Additive effects are theoretically possible but require individual clinical assessment.
Patients with allergies to plants in the Urticaceae family (including fig mulberry) or documented birch pollen allergy carry elevated risk for allergic reactions and should exercise caution or avoid nettle root supplementation.
Clinical Recommendations and Patient Selection
Candidate Populations
Nettle root supplementation may be considered in the following clinical contexts:
- Men with mild-to-moderate LUTS (IPSS 8–19) secondary to BPH who decline or are not candidates for pharmaceutical therapy
- Patients experiencing bothersome nocturia (≥2 episodes per night) as a predominant symptom
- Men intolerant of 5-alpha reductase inhibitors (particularly those with sexual dysfunction concerns, given nettle root's more favorable sexual side effect profile)
- Patients seeking adjunctive therapy combined with existing alpha-blocker or 5-alpha reductase inhibitor regimens, pending further efficacy data
Who Should Avoid Nettle Root
The TriCountyUrology.org Medical Team recommends avoiding nettle root supplementation in:
- Men with severe LUTS (IPSS >19) or acute urinary retention—pharmaceutical interventions or urology referral is indicated
- Patients with documented Urticaceae family allergies or significant birch pollen allergy/atopy
- Men concurrently using warfarin or other anticoagulants without cardiology/urology consultation (due to theoretical vitamin K interaction)
- Individuals with active kidney disease or volume depletion (diuretic risk)
- Pregnant or nursing individuals (safety data are absent)
Monitoring Parameters
Clinical assessment should include baseline International Prostate Symptom Score, post-void residual volume measurement (if feasible), and baseline blood pressure. Follow-up evaluation at 4–6 weeks and 12 weeks post-initiation is appropriate to objectively assess symptomatic response. Lack of meaningful IPSS improvement (≥3-point reduction) after 12 weeks warrants consideration of alternative therapies or urology referral.
Summary Assessment
Clinical evidence indicates that nettle root extracts at standardized doses of 300–600 mg daily may provide moderate symptomatic relief for men with mild-to-moderate LUTS secondary to benign prostatic hyperplasia, with particular effectiveness for nocturia reduction. The mechanism appears to involve symptomatic palliation rather than fundamental prostate size reduction, and efficacy is modestly inferior to pharmaceutical 5-alpha reductase inhibitors but with improved sexual side effect tolerability. Future research should prioritize head-to-head effectiveness comparisons, characterization